Home / Market News / $MDCX
benzinga Corporate Catalyst Impact 65/100 ● neutral

Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer

Sep 29, 2026, 11:31 AM UTC · Primary ticker $MDCX

Medicus Pharma has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix, its drug for advanced prostate cancer patients with increased cardiovascular risk. This move signals progress in the drug's development and potential path to market, which could be a significant value driver for the company if successful.

Medicus Pharma announced the submission of an optimized seamless Phase 2b/3 registration-intent protocol for Teverelix to the FDA. This is a crucial step in the drug development process for Teverelix, an investigational GnRH antagonist targeting advanced prostate cancer patients with high cardiovascular risk. The 'registration-intent' aspect suggests the company aims for this trial to support a New Drug Application (NDA), potentially accelerating the drug's path to market. This development is positive for MDCX as it indicates progress in their pipeline and could lead to significant long-term revenue if Teverelix proves successful in trials and gains approval. Short-term, it may generate investor interest, while long-term implications depend on trial outcomes and market adoption.

$MDCX positive Advancement of key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.